Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 14Active not recruiting 7Not yet recruiting 6Terminated 4Completed 4Withdrawn 2Approved for marketing 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 4

Conditions

Carcinoma, Non-Small-Cell Lung 129Breast Neoplasms 113Neoplasms 97Neoplasm Metastasis 78Melanoma 73Leukemia, Myeloid, Acute 69Colorectal Neoplasms 69Prostatic Neoplasms 60Multiple Myeloma 52Lung Neoplasms 52Ovarian Neoplasms 51Squamous Cell Carcinoma of Head and Neck 46Triple Negative Breast Neoplasms 42Recurrence 41Carcinoma, Renal Cell 39Carcinoma, Hepatocellular 39Pancreatic Neoplasms 36Myelodysplastic Syndromes 36Glioblastoma 35Brain Neoplasms 34Lymphoma 31Stomach Neoplasms 30Lymphoma, Non-Hodgkin 30Endometrial Neoplasms 30Leukemia 29Lymphoma, Large B-Cell, Diffuse 28Head and Neck Neoplasms 28Uterine Cervical Neoplasms 26Cholangiocarcinoma 26Urinary Bladder Neoplasms 24

Interventions

Trastuzumab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × HER2-positive Breast Cancer × 1 year × Clear all
NCT03738553 2026-05-04

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

University of Washington

Terminated
13 enrolled
Breast

HER2-positive Breast Cancer

NCT07166367 2025-09-10

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

National Cancer Centre, Singapore

Phase 2 Terminated
3 enrolled
Breast

HER2-positive Breast Cancer

NCT01722890 2025-07-08

CharactHer. ICORG 12-09, V3

Cancer Trials Ireland

Terminated
130 enrolled
Breast

HER2-positive Breast Cancer

NCT05511844 2025-07-04

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Orum Therapeutics USA, Inc.

Phase 1 Terminated
25 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡